of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Entry into a Material Definitive Agreement. Symatese License Amendment - Addition of Australia, New Zealand and Canada On August 3, 2026, Evolus Pharma B.V. (“Evolus Europe”), a wholly owned subsidiary of Evolus, Inc. (the “Company”), and Symatese Aesthetics S.A.S. (“Symatese”) entered into an amendment (the “Amendment”) to the License, Supply and Distribution Agreement dated December 20, 2023 (the “Agreement”), which the Company previously disclosed in a Current Report on Form 8-K filed on D…

Entry into a Material Definitive Agreement. IBSA License Agreement - Profhilo ® On July 7, 2026, Evolus, Inc. (the “Company”) and IBSA Institut Biochimique SA (“IBSA”) entered into a License, Supply and Distribution Agreement (the “Agreement”), pursuant to which IBSA granted to the Company an exclusive right and license to develop, commercialize and distribute Profhilo ® , an injectable hyaluronic acid product for skin-quality applications (the “Initial Product”), in the United States for use…

of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Director — Vikram Malik: Mr. Vikram Malik was reclassified from Class III to Class II director to restore balance among the classes of directors.

of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Entry into a Material Definitive Agreement. On March 3, 2026, Evolus, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with Eclipse Business Capital LLC, as administrative agent (the “Agent”) and the lenders party thereto. The Loan Agreement provides for a senior secured asset-based revolving credit facility of up to $30.0 million (the “Revolving Credit Facility”), subject to a borrowing base formula based on eligible accounts receivable and eligible inve…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in

of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

CFO — Sandra Beaver: Sandra Beaver resigned as CFO to pursue another opportunity.

of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in

Entry into a Material Definitive Agreement. On May 5, 2025, Evolus, Inc. (the “Company”) entered into an amended and restated loan agreement (the “A&R Loan Agreement”), with BPCR Limited Partnership, as a lender (“BCPR”), BioPharma Credit Investments V (Master) LP, as a lender (together with BCPR, the “Lenders”), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent” and, collectively with the Company and the Lenders, the “Parties”), amending a…

of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

The filing is about the approval of a new Employee Stock Purchase Plan, which does not involve any management changes.

of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Director — Robert Hayman, Simone Blank: Directors Robert Hayman and Simone Blank are stepping down as part of the company's board refreshment efforts.

Entry into a Material Definitive Agreement. On March 11, 2024, Evolus, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners, LLC and Stifel, Nicolaus & Company, Incorporated as representatives of the underwriters named in Schedule A thereto (together, the “Underwriters”), in connection with the underwritten public offering, issuance and sale by the Company (the “Offering”) of 3,554,000 shares (the “Firm Share…

of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Entry into a Material Definitive Agreement. Dermal Filler License Agreement - Europe On December 20, 2023, Evolus Pharma B.V. (“Evolus Europe”), a wholly owned subsidiary of Evolus, Inc. (the “Company”) and Symatese Aesthetics S.A.S. (“Symatese”), entered into a License, Supply and Distribution Agreement (the “Agreement”), pursuant to which Symatese granted to Evolus Europe an exclusive right to commercialize and distribute four dermal filler product candidates, which are referred to as: (i)…